bimodal age distribution pattern with a peak between 5 and 14 years in children and 50 and 74 years in adults, although the tumor has been reported in all age groups. 1, 16, 20 They account for 2%-5% of primary intracranial neoplasms overall 16, 20, 31, 32 and 6%-13% of intracranial tumors in children. 1, 14, 16, 20 Craniopharyngiomas rarely undergo malignant degeneration but are difficult to cure and pose significant difficulties in the establishment of an optimal therapeutic protocol. Treatment should focus on the relief of symptoms, avoidance of treatment-related morbidity, preservation of quality of life, and prevention of recurrence with extension of survival. Complete tumor removal can be curative, and excision followed by irradiation in cases of residual tumor is the main treatment option. 20, 39 However, increased recurrence rates usually necessitate multimodality treatments (surgery, radiotherapy, stereotactic radiosurgery, intracystic irradiation, local/intracystic chemotherapy, or systemic chemotherapy). In every case, treatment should be tailored to the individual based on age, presenting symptoms, tumor characteristics, prior treatment, treatment tolerance, and comorbidities.
For the last 12 years in our department, EES has been used for the treatment of every craniopharyngioma except purely intraventricular tumors. The aim of the present study was to describe the results of this surgical approach for the management of craniopharyngiomas and to analyze outcome in both the pediatric and the adult age groups. We also discuss the surgical success of the endonasal approach, compare its results with those for open and microscopic transsphenoidal approaches, and provide a review of the literature.
Methods

Patient Population
With approval from the institutional review board, we retrospectively reviewed the medical files and imaging studies of patients with craniopharyngiomas treated via EES at the University of Pittsburgh Medical Center in the period from June 1999 to April 2011. In every case, the diagnosis had been histologically confirmed. All patients had been preoperatively evaluated with MRI and CT scanning of the brain and skull base. Tumor volume was approximated by a modified ellipsoid volume, that is, (A × B × C)/2, where A, B, and C are the maximum diameters of the craniopharyngioma in each of the 3 dimensions.
Evaluation of Outcome
Clinical outcome after EES had been assessed with postoperative visual tests (visual acuity and visual fields), endocrinological studies, and clinical examination. Postoperative obesity was evaluated based on BMI and BMIfor-age/-sex charts for children; these results were available in only 20 adults but in 16 of the 17 children.
We evaluated the degree of tumor resection by performing volumetric analysis of the postoperative MR images compared with preoperative images. In most cases, immediate postoperative MRI had been performed within a few days after surgery to be used as a baseline for further imaging follow-up. The degree of resection had been confirmed on the 3-month postoperative MRI study in all but 5 patients; 3 were lost to follow-up and 2 died within 3 months following surgery. During our review, the volume of residual craniopharyngioma was calculated with the same mathematic formula ([A × B × C]/2) used for the initial tumor measurement. In residual tumors, we considered the degree of resection to be near total when > 95% of the tumor was resected, subtotal when ≥ 80% of the tumor was resected, and partial when < 80% of the tumor was removed.
Results were analyzed for the whole cohort and separately for the adult and pediatric populations. Resection and recurrence rates for every studied tumor characteristic were compared using the chi-square or Fisher exact test, as appropriate. A p value < 0.05 was considered statistically significant. Data were collected using Microsoft Excel 2010 (Microsoft Corp.) and analyzed using SAS, version 9.3 (SAS institute Inc.).
Results
Clinical Presentation
Sixty-four patients (47 adults and 17 children) with craniopharyngioma were identified. The mean age of patients was 40 years (range 4-82 years) with a male/female ratio of 1.6:1. Forty-seven patients had presented with primary craniopharyngioma and 17 with recurrent. All of the 17 previously treated patients had undergone surgery elsewhere (multiple surgeries in 5 cases), including craniotomy (13 patients), transsphenoidal surgery (5 patients), and stereotactic cyst aspiration (2 patients); 8 of the 17 had had additional radiation therapy and 1 had received chemotherapy. In the adult population, the mean age was 51 years (range 28-82 years) and there was a male predominance (male/female ratio of 1.5:1). Thirty-four adults (72%) had a primary craniopharyngioma. In the pediatric population, the mean age was 9 years (range 4-18 years) and there was a male predominance (male/female ratio of 1.8:1). Thirteen children (76%) had presented with a primary craniopharyngioma.
The most common clinical presentation in the entire cohort was visual impairment, which occurred in 44 patients (68.8%), followed by complete or partial pituitary dysfunction (62.5%), obesity (51.8%), headache (42.2%), and DI (29.7%). In the adult population, visual impairment occurred in 80.8% of patients, hypopituitarism in 66%, and obesity in 55%. (In the adult group it was difficult to differentiate between hypothalamic obesity and obesity due to lifestyle or other factors.) In the pediatric population, besides visual deficit and hypopituitarism (35.3% and 52.9%, respectively), common symptoms were central obesity (43.8%) and headache (64.7%). As expected, patients who had presented with recurrent, previously treated tumors had a higher incidence of pituitary dysfunction (76.5% of patients vs 57.4% of those with primary craniopharyngiomas) and a higher rate of DI (76.5% of patients vs 12.8% of those with primary tumors). Moreover, obesity was remarkably higher in previ-ously treated patients (73.3% vs 43.9%). Table 1 summarizes the presenting symptoms in the different age groups (adults vs children), according to previous treatment status (primary vs recurrent tumor), and in the whole cohort.
Imaging Findings
The average tumor volume in the whole cohort was 9.6 cm 3 (range 0.96-68.5 cm
3
), and the maximum tumor diameter varied from 1.3 to 6.4 cm. In adults, the average tumor volume was 6.6 cm 3 (range 0.96-31.4 cm
) and the maximum tumor diameter ranged from 1.3 to 5.1 cm. Tumors were bigger in the pediatric group with an average volume of 17.7 cm 3 (range 1.5-68.5 cm
, and the maximum tumor diameter ranged from 1.8 to 6.4 cm.
Tumor location and extension were quite irregular in many cases. All tumors had a suprasellar component, and 39 also occupied the sella (60.1%). All of the craniopharyngiomas also had some degree of hypothalamic involvement. Extension into the third ventricle, which was evaluated on preoperative MRI and confirmed intraoperatively, occurred in 21 cases (32.8%) in the entire cohort. In many cases, the preoperative MRI impression of tumor extension into the third ventricle was incorrect; usually the tumor expanded against the floor of the third ventricle, which remained intact (Fig. 1) . Extension to the interpeduncular cistern was found in 34 cases (53.1%). Cavernous sinus involvement was rare and evident mainly in the adult group (10.6%), while extreme lateral extension to the cerebellopontine angle was found only in children (11.8%). Fifty-eight (91%) of the tumors showed heterogeneous enhancement on MRI after contrast administration, 4 showed homogeneous enhancement, and 2 had a purely cystic appearance. Table 2 summarizes the tumor imaging findings in adults, children, and the entire cohort.
Surgical Management and Adjuvant Treatment
All patients underwent EES as the initial treatment modality. The goals of surgery were symptom relief and the avoidance of surgery-related morbidity with GTR desired in every case possible. However, in many cases GTR was considered overly dangerous because of tumor infiltration of or adherence to vital neurovascular structures (for example, the hypothalamus or optic chiasm); in such cases, residual tumor was intentionally left behind. Fifty patients (78.1%) underwent a single EES; and 5 (7.8%), a staged EES. In 9 cases (14%), resection was followed by radiotherapy: radiosurgery in 6 cases, conventional radiotherapy in 2, and proton beam in 1. Endoscopic endonasal surgery combined with radiotherapy was more often used in the adult group than in the pediatric group (8 patients vs 1 patient).
During a mean follow-up of 38 months (range 1-135 months), 22 patients (34%) had a tumor recurrence (15 adults and 7 children) and were treated with reoperation in 6 cases (EES in 5 and open craniotomy in 1), radiosurgery alone in 1, surgery (EES in 7 and craniotomy in 1) combined with radiotherapy (intracystic irradiation with 32 P in 3 patients and radiosurgery in 7) in 8 patients, systemic interferon in 1 pediatric patient, and close follow-up (no adjuvant treatment so far) in 6 clinically asymptomatic patients. Open craniotomies, although never used as the initial ap- proach in this cohort, were performed in 3 cases of craniopharyngiomas that recurred either in the third ventricle or lateral to the optic nerve/supraclinoid carotid artery. Table 3 summarizes all treatment modalities used for the management of craniopharyngioma both initially and for recurrences in adults, children, and the entire cohort.
Degree of Tumor Resection
As previously mentioned, the goals of surgery are symptom relief, the avoidance of surgery-related morbidity, and GTR whenever possible. When GTR is considered harmful, we intentionally leave tumor capsule attached to vital surrounding neurovascular structures with the aim of resecting > 95% of the tumor; we have found that this degree of resection can provide good results while limiting major morbidity. For adults in whom GTR may be dangerous, we believe that near-total surgical removal combined with postoperative irradiation represents a better alternative than aggressive surgery with the aim of GTR. We have probably been more aggressive with the pediatric population given the radiotherapy restrictions in this age group. As a result, the GTR rate after EES was 37.5% (24 patients) overall and was higher in children (9 patients [52.9%]) than in adults (15 patients [31.9%]; p = 0.12; Fig. 2 ). Analyzing our results based on the goal of maximum safe resection (> 95% of the tumor), the overall success rate was 71.9% (46 patients) and, more specifically, 61.7% in adults (29) and 100% in children (17; p = 0.002). Besides this significant difference in resection rates; tumor location, tumor extension, and previous treatment did not influence the success rates of EES when we analyzed the data with the goal of either GTR or maximum safe resection ( in the majority of adult patients, so it is difficult to have conclusions as regards the overall study. However, weight changes were well studied in the pediatric population and the results are analyzed below.
Adult Population. The majority of adults (38 patients) presented with visual deficits, which improved or resolved in 32 (84.2%). In 5 adults (13.2%), preoperative visual deficits remained unchanged after EES, and 1 elderly patient (2.6%) experienced a temporary deterioration of his preexisting impaired vision in the immediate postoperative course. Further deterioration or new visual impairment in this cohort was transient. Improvement or normalization of preexisting hypopituitarism occurred in 7 adults (22.6%) and affected thyroid function in 2, gonadal function in 4, GH restoration in 2, and normalization of elevated prolactin levels in 3. The condition in over half of the adults (51.6%) with preoperative pituitary insufficiency remained unchanged, including 10 who had presented with recurrent craniopharyngiomas and panhypopituitarism after previous treatment. Worsening of preexisting hypopituitarism occurred in 8 cases (25.8%), affecting the HPA axis in 7 cases, the HPT axis in 3, the HPG axis in 1, and GH secretion in 2. New pituitary insufficiency in adults with normal pituitary function preoperatively was found in 6 cases (37.5%) and included a deficit in the HPA axis in 6 (37.5%), the HPT axis in 6 (37.5%), the HPG axis in 3 (18.7%), and GH secretion in 1 (6.2%). Preexisting DI was never resolved; transient DI occurred in 11 patients, permanent DI developed in 10 (32.3%) after surgery. Five patients presented with increased intracranial pressure, and 2 of them had received a shunt after previous treatment; shunt placement was necessary in the other 3 patients as well. As mentioned above, obesity is difficult to exclusively associate with hypothalamic dysfunction in this age group and thus we did not closely track adults for weight changes after EES. With the available data, however, we did find that all obese adults remained obese following surgery (9 patients), and 2 overweight adults (11.1%) became obese postoperatively. Table 5 provides a summary of the clinical outcomes in the adult population.
Pediatric Population. Children with craniopharyngioma presented mainly with headache (11 patients), which was resolved in every case after EES. Six children had preoperative visual impairment that improved or even normalized after treatment; there was no visual worsening or new deficit in this cohort. Improvement of preexisting hypopituitarism occurred in only 1 patient (11.1%) and affected both the HPG axis and GH secretion. Preexisting hypopituitarism remained unchanged in one-third of the patients after EES, including 2 who had presented with recurrent craniopharyngioma and panhypopituitarism after previous treatment. Five patients (55.5%) showed further pituitary dysfunction in the HPA axis (4 patients), the HPT axis (2 patients), the HPG axis (2 patients), and GH secretion (1 patient). All of the previously endocrinologically intact children (8 patients) showed some degree of postoperative pituitary dysfunction requiring hormonal replacement therapy. New pituitary insufficiency affected the HPA axis in 7 cases (87.5%), the HPT axis in 8 (100%), and GH secretion in 3 (37.5%). Preexisting DI was never resolved; transient DI occurred in 1 patient (7.1%) and permanent DI developed in 11 (78.6%) after surgery. Four patients presented with hydrocephalus (2 of them had received a shunt after previous treatment); after EES, hydrocephalus resolved in every case but required shunt revision in 1 of the previously treated cases. One patient who presented with CN VI palsy showed complete recovery 6 months after EES. Among the 7 children who presented with central obesity, 6 had available postoperative data on their BMI-for-sex/-age. Five (83.3%) showed unchanged weight, and 1 (16.7%) lost weight and was moved to the overweight category. Among the 9 children who were either normal (8 patients) or overweight (1 patient) before surgery, 3 (33.3%) became obese, 5 (55.5%) maintained their weight, and 1 (11.1%) became overweight after surgery. Table 6 provides a summary of clinical outcomes in the pediatric population.
Surgical Complications
New hypopituitarism and permanent DI have already been described in detail above. Overall, CSF leakage occurred in 23.4% of patients (27.7% in adults and 11.8% in children). It is important to note that EES began being used in children after 2007 when the skull base defect was routinely reconstructed with the vascularized nasoseptal flap, which is probably the reason for the difference in leakage rates. The CSF leakage rates in adults were significantly different between the flap and no-flap EES groups (p = 0.0006): among 17 adults who underwent no-flap reconstruction, 58.8% (10) had a CSF leak, whereas a leak occurred in only 10% (3) of the 30 adults who had vascularized flap reconstruction (essentially the same as in the pediatric group). Cerebrospinal fluid leakage was treated with reoperation alone (6 patients), lumbar drain placement alone (2 patients), or reoperation combined with lumbar or external ventricular drain placement (7 patients). Meningitis developed in 2 of the patients with a CSF leak. Signs and symptoms of meningitis developed in 5 patients and were managed with antibiotics without further complications. Hydrocephalus after EES occurred in 7 patients (12.7%) who were all treated with ventriculoperitoneal shunt placement; 3 of the 7 experienced postoperative CSF leakage. Only 1 of these 7 patients had preoperative papilledema, and none had preoperative radiographic evidence of hydrocephalus. Most of the patients with postoperative hydrocephalus had relatively large tumors (exceeding 3.2 cm in their maximum diameter in 5 cases), and 5 of the 7 had tumor extension into the third ventricle. Postoperative CN palsies (affecting CN VI in 3 cases and CN III in 2 cases) were all transient and occurred more often in children (17.6% vs 4.2% in adults), which may be a result of a larger tumor size or more aggressive surgical manipulation to achieve higher rates of tumor resection. Transient SIADH developed in 3 patients and was managed with water restriction. Some more rare complications occurred in the pediatric group and included 1 case of epidural hematoma from pin placement, requiring craniotomy for hematoma evacuation; 1 case of intraventricular hematoma and resultant hydrocephalus, managed with reoperation and shunt placement; and 1 case of subdural hematoma following external ventricular drain removal, managed via observation without further complications. No death occurred in the immediate postoperative course, that is, within 1 month after EES. Table 7 summarizes the main complications after EES in adults, children, and the entire cohort.
Adjuvant Treatment, Recurrences, and Follow-Up
The mean follow-up was 38 months (range 1-135 months) for the entire cohort, 39 months (range 1-135 months) for adults, and 35.3 months (range 11-59 months) for children. During this period, 22 patients (34.4%) had tumor recurrence. Although resection rates after initial EES were higher in children, this age group showed a slightly higher recurrence rate than adults in the same time period (41.2% and 31.9%). In evaluating recurrence rates based on the degree of resection, we found no statistical significance (p = 0.43). Comparing recurrence rates between GTR and non-GTR cases revealed no significant difference (p = 0.22). Additionally, age, tumor location, or previous treatment did not have an important influence on recurrence, as shown in Table 8 . However, it is important to note that the relatively short follow-up in this study may have resulted in a small number of recurrences at the present time and moderate power for a safe statistical analysis. The recurrence-free period was 17.1 months (range 3-52 months) in the entire cohort, 15.1 months (range 3-33 months) in adults, and 19.6 months (range 4-52 months) in children.
Adjuvant treatment either initially or for the management of recurrent craniopharyngioma has already been summarized in Table 3 . Radiotherapy following EES was more often used in adults than in children (17% vs 6% for primary tumors and 40% vs 28.6%, respectively, for recurrent tumors; Fig. 3 ). As with primary tumors, recurrences in children were more often treated with surgery alone (42.8% vs 20% in adults). One child with a multiply recurrent craniopharyngioma received systemic chemotherapy with interferon and has remained free of disease for more than 2 years. Among the 7 adults who received adjuvant radiotherapy after EES, 2 with near-total tumor resection demonstrated no evidence of tumor on the most recent MRI and 5 showed a decrease in residual tumor. At the most recent follow-up for each patient, 24 patients (37.5%) were free of tumor, 6 (9.4%) had decreased residual tumor, 30 (46.9%) had stable residual tumor, and 4 (6.2%) had increased tumor; repeat surgery was planned for 2 of the latter 4 patients, whereas observation with further imaging studies was planned for the other 2. Although there was no operative mortality (death in the immediate postoperative course or within 1 month after EES) during the follow-up, 9 patients have died. An elderly patient died 2 months after EES as a result of the late complications of pneumonia and acute respiratory distress syndrome, although his surgery had been uneventful and he had been discharged on the 6th postoperative day without complaints. Another elderly patient died within 3 months after EES as a result of a fall that caused a subdural hematoma. All other deaths occurred years after EES and were not associated with the tumor.
Discussion
The surgical challenge that craniopharyngiomas represent and the frequent need for adjuvant treatment has been extensively discussed in the literature. 9, 12, 17, 19, 20, 27, 39 Traditionally, transsphenoidal or transcranial surgery is chosen based on the location (intrasellar or suprasellar) of the mass, its consistency, the degree of calcification, and the shape and size of the tumor. 16, 20, 27 The standard procedure for many years has been the transcranial route, which provides access to the suprasellar cisterns and direct visualization of the vital structures surrounding the tumor. 16 In selected cases, transsphenoidal or extended transsphenoidal surgery has been used to achieve tumor excision.
4,9,17,25-27
Endoscopic endonasal surgery has been used for the treatment of craniopharyngiomas in a few institutions over the last decade with good results.
2,3,5,11,12,21 Initially, it was applied to selected tumors with a purely sellar location, but as surgical experience and technology have advanced, EES has been used in our department for every suprasellar craniopharyngioma regardless of its extension (Fig. 4) , except for purely intraventricular tumors. The surgery requires a multidisciplinary team with significant EES experience and advanced equipment (angled endoscopes, endoscopic surgery instruments, image guidance, and neurophysiological monitoring) for safe results. This approach provides direct access to the skull base, the suprasellar and parasellar regions, the interpeduncular cistern, and the third ventricle. It allows direct visualization for dissecting the optic apparatus, hypothalamus, and pituitary stalk, maintaining their blood supply and functional integrity and avoiding complications associated with brain retraction and extensive craniotomies.
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Finally, the endoscopic endonasal approach allows direct access to the long axis of craniopharyngiomas, a factor well recognized as critical for maximal, safe tumor resection.
It is important to note some limitations of our study.
First of all, the recent application of EES for the resection of craniopharyngiomas means there is a relatively short follow-up (mean 38 months). Given this limitation, we cannot provide long-term results and survival rates for patients with craniopharyngioma who have undergone EES. Additionally, this study is retrospective and nonrandomized. However, given that all patients with craniopharyngioma, with the rare exception of those with purely intraventricular tumors, are subjected to EES at our institution, we believe that this study lacks selection bias.
Resection Rates-Defining the Goals of Surgery
Irregular tumor extension and adherence to or infiltration of vital surrounding neurovascular structures do not allow a clear line of cleavage, making complete resection difficult and potentially hazardous to critical brain areas. The rates of GTR in the literature are variable among the different approaches and range from 16% 20 to 90%. 40 Although Yaşargil et al. 40 have reported a 90% GTR rate, that rate was based on the surgeon's impression alone given that postoperative MRI was not available in the majority of cases. Additionally, their intraoperative/early postoperative mortality rate was 9% and overall mortality was 16.7%. Indeed, there appears to be a clear relation between the rate of GTR and perioperative mortality. 10 Yang et al. 39 found that, regardless of the approach, the overall GTR rate after craniopharyngioma surgery is 58%. In our cohort, the overall GTR rate was only 37.5%; however, GTR was not considered safe and was therefore not attempted in every patient.
We believe that the optimal surgical approach should minimize the risk of damage to vital structures, and thus when the tumor capsule cannot be separated from vital neurovascular structures, we prefer to leave it behind and perform postoperative radiosurgery in adults and close follow-up in children. When GTR becomes dangerous, we consider surgical success a resection rate of at least 95% of the initial tumor mass, which was achieved in 71.9% of our patients along with perioperative mortality of 0%. This strategy-that is, of near-total resection combined with subsequent radiation as an alternative to GTR when the surgical risks overpower the potential benefithas already been advocated by other surgeons. 24, 28, 36 In fact, a recent meta-analysis 39 has confirmed that subtotal resection with adjuvant irradiation results in similar rates of long-term disease control and recurrence as compared with those for primary GTR. Besides this recent trend in the surgical management of craniopharyngiomas that supports less aggressive approaches, there is no consensus in the literature on the acceptable amount of tumor to leave behind. We believe that GTR should remain the goal of surgery, and when this is not safe we should attempt the maximum (> 95%, if possible) tumor resection and apply radiation therapy for any residual tumor. However, to avoid the side effects of radiation in the young brain, 23 we have offered radiosurgery after initial EES to only one 16-year-old patient with residual tumor, and we closely followed up the rest of the children to offer adjuvant treatment in cases of recurrence.
As illustrated in Table 4 , EES is equally effective for primary and recurrent craniopharyngiomas. The safety and efficacy of EES for residual or recurrent craniopharyngiomas, regardless of the previous surgical route, has already been described by Cavallo et al. 3 This equivalent efficacy contrasts with the effectiveness of open approaches for recurrent tumors in which scar tissue and adhesions along the surgical path from previous surgeries and radiation decrease the possibility of successful excision at reoperation; the rates of total tumor removal in such cases decrease dramatically to 0%-25% and increase perioperative morbidity and mortality to 10.5%-24%. 20 Clearly, scarring that occurs within any tumor can increase the difficulty of resection upon recurrence. In the case of repeat endonasal surgery, however, the cavity for approach remains widely open and, if a patient previously underwent craniotomy, provides fresh access.
We found that EES can provide equivalent resection rates between intrasellar tumors with suprasellar extension and purely suprasellar craniopharyngiomas. This finding contradicts the generally accepted notion that suprasellar craniopharyngiomas should be approached transcranially. 9, 17, 19, 27, 40 Moreover, intraventricular tumor extension is not a limitation for EES. Indeed, the GTR rate was higher for intraventricular tumors than for extraventricular ones (42.9% vs 34.9%). The tumor, growing in the cranial direction, creates a corridor to the third ventricle; therefore, manipulation of the surrounding vital neurovascular structures can be avoided (Fig. 5) . Furthermore, with the view from below, it is possible to identify and dissect the arachnoid layer between the dome of the craniopharyngioma and the floor of the third ventricle in the numerous cases in which the tumor expands against the floor of the ventricle without penetrating it. 38 Finally, the walls of the third ventricle and the dissection plane (or lack thereof) with the hypothalamus can be well visualized to determine the safety of resection.
10 This ability to visualize critical interfaces further supports the resection philosophy espoused above.
The single significant factor affecting resection rates is patient age (p = 0.002). Children are very vulnerable to recurrences, and this fact led us to pursue the intentional surgical aggressiveness that we apply based on age. As other authors have advocated, radical resection at presentation offers the best chance of disease control and potential cure with acceptable morbidity in pediatric craniopharyngiomas. 7 Thus, when tumor infiltrates the infundibulum and cannot be fully dissected, we prefer to sacrifice pituitary function to achieve radical resection (unless the child is at or near puberty). Indeed, the GTR rate in children was 52.9%, the highest in our cohort. However, the same surgical aggressiveness cannot be applied when infiltration of the hypothalamus occurs, risking permanent and devastating neurological sequelae 34 or hypothalamic dysfunction. This limitation led to near-total resection in the rest of the pediatric cases (47.1%). Although surgical aggressiveness in pediatric cases has resulted in significantly higher resection rates in children (> 95% in 100% of children vs 61.7% of adults), it has also caused higher rates of new pituitary dysfunction and DI in this age group, as discussed below.
Clinical Outcome
Direct comparison of the results of transcranial surgery with those of TSS and EES is probably not valid because of selection bias. Transsphenoidal surgery and EES (based on limited reports) have traditionally been reserved for small sellar tumors and/or sellar enlargement, and purely suprasellar craniopharyngiomas have generally been considered to be unmanageable by TSS. 4, 9, 17, 19, 27 Thus, the favorable results of TSS are often attributed to limited case selection, which excludes the more demanding large, purely suprasellar craniopharyngiomas with intraparenchymal and intraventricular extension. In the present study, all patients were treated with EES. We used open craniotomies in only 3 tumors that recurred either in the third ventricle or lateral to the optic nerve/supraclinoidal carotid artery.
Visual Outcome. In general, the published literature has shown that transcranial surgery is associated with worse visual outcomes in comparison with those for TSS and EES. 8, 10 According to the extensive experience of Fahlbusch et al. 9 with 168 craniopharyngiomas, visual improvement occurred in 63% of patients after transcranial surgery and 73% after TSS; visual deterioration occurred only in the transcranial group and accounted for 14.3% of these cases. Similarly, after managing 86 craniopharyngiomas, Chakrabarti et al. 4 noticed visual improvement in 61% of the transcranial cases versus 87% of TSS cases; vision worsened postoperatively in 17% of the transcranial cohort versus 3% of the transsphenoidal cohort. In a microscopic TSS study of 57 cases, Maira et al. 27 noted vision improvement in 84.2% of the patients, which was similar to the 85.7% of patients in the EES experience of Campbell et al. 2 Note that the latter study had a vision deterioration rate of 7.1%. In an account of their experience with TSS for pediatric craniopharyngiomas, Jane et al. 17 documented visual improvement in 64% of children and deterioration in 14%.
In an earlier report of our initial experience with EES for the treatment of suprasellar craniopharyngiomas,
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93% of the patients showed postoperative visual improvement and 0% had visual deterioration. In keeping with our surgical principles, visual improvement in the current study overall was 86.4% with 0% permanent visual deterioration. Notably, 100% of the pediatric population had visual improvement versus 84.2% of adults; the lower success rate in adults may represent the higher rate of previously treated patients in this group (27.7% with surgery and/or radiotherapy) who presented with permanent visual deficits or the resiliency of children.
Endocrinological Outcome. Based on a recent review of the craniopharyngioma literature, 10 rates of new endocrinopathy in transcranial studies have ranged from 24% to 66% for panhypopituitarism and from 43% to 79% for DI; in transsphenoidal studies, 18%-67% of patients demonstrated panhypopituitarism and 8%-48% exhibited permanent DI. Again, the favorable transsphenoidal results may reflect selection bias. While sellar craniopharyngiomas usually displace the pituitary stalk, suprasellar craniopharyngiomas infiltrate the stalk and are more likely to present with postoperative pituitary dysfunction due to surgical manipulation. The latter tumors are usually counted among transcranial series. Some authors believe that pituitary stalk transition and resultant DI are acceptable to accomplish total tumor removal. 15 We have adopted the new trend of near-total tumor resection combined with radiotherapy when GTR is contraindicated. The outcome in adults in the present study was 37.5% with new anterior pituitary dysfunction and 32.3% with permanent DI, without any bias for tumor selection. Although these results and the overall incidence of new hypopituitarism in 51.9% of patients and permanent DI in 46.7% of pa- tients concur with those in the transsphenoidal literature, it is worth noting the different endocrinological outcome in pediatric patients. Since children are more vulnerable to late treatment failures and side effects from radiation therapy, including endocrinopathies, vasculopathies, and secondary tumors, 23 we remain surgically aggressive in this age group. This principle explains the higher pediatric rates of postoperative new hypopituitarism (86.7%) and new DI (78.6%).
Central Obesity. Central obesity due to hypothalamic eating disorders is a major adverse effect in children and adolescents with craniopharyngioma. Increased BMI at the diagnosis of craniopharyngioma is a significant risk factor for severe obesity and correlates with the severity of hypothalamic damage. 30 All of our pediatric craniopharyngiomas had some degree of radiographic hypothalamic involvement, and the rate of obesity at diagnosis was 43.8%, which was similar to other reported rates.
6,29
New-onset obesity in children has been documented at over 50% after transcranial surgery 30 and 37% after TSS. 17 The incidence of new obesity following EES was 33.3% in our experience.
Obesity in adults with craniopharyngioma may not be exclusively associated with hypothalamic dysfunction but may represent an unhealthy lifestyle and/or genetic predisposition. Postoperative obesity in adults is rarely discussed in the literature. Chakrabarti et al. 4 found hyperphagia in 61% of patients with craniopharyngioma after transcranial surgery and in 40% after transnasal surgery. In our experience, 11.1% of the adults with craniopharyngioma with available postoperative data were newly obese after EES, but it is unclear if this rate represents true hypothalamic damage or if it is the result of hypopituitarism or lifestyle factors. In any case, obesity confers significant morbidity and mortality and may further affect the quality of life of these patients.
Surgical Complications
Evidence of new endocrinopathies and visual deterioration was discussed earlier and, based on the current literature, was higher in transcranial than in transsphenoidal studies. 4, 8, 9 One of the major problems of transnasal approaches (either microscopic transsphenoidal or endoscopic) has been postoperative CSF leakage. Maira et al., 27 who used TSS, noted CSF leaks in 17.5% of their cases. In endoscopic studies, de Divitiis et al. 5 and Campbell et al. 2 reported CSF leak rates of 20% and 37.5%, respectively. Our early institutional experience 12 with EES in treating 16 suprasellar craniopharyngiomas included a CSF leak rate of 58%. In the present study and after the introduction of the vascularized nasoseptal flap for skull base reconstruction, 13, 22, 41 the overall CSF leak rate decreased dramatically to 23.4%. Indeed, among the patients with craniopharyngioma who underwent reconstruction with the vascularized nasoseptal flap (47 patients), only 5 experienced a CSF leak, which means a CSF leakage rate of 10.6% when this technique is used. The incidence of postoperative meningitis, usually associated with CSF leaks, remains low.
2,4,9,12,17
Postoperative hydrocephalus requiring treatment has ranged from 0% to 21.4%. 2, 9, 17, 27 Our rate was consistent with that at 12.7%, and we treated hydrocephalus with ventriculoperitoneal shunt placement. Other surgical complications, such as hematoma, seizures, pneumocephalus, wound-healing problems, and SIADH, have been reported in the literature but are not clearly associated with the surgical route.
2,9,17
Other than the evidence of new obesity in 3 children, none of our patients experienced postoperative hypothalamic dysregulation or cognitive decline, both of which have been described by other authors who perform more aggressive tumor resection to achieve higher GTR rates. 4, 9, 17 Since hypothalamic damage can result in devastating sequelae, we continue to strongly support less aggressive dissection when the tumor infiltrates this vital neurological structure, even if doing so results in lower rates of complete tumor resection.
Perioperative mortality has been directly associated with higher rates of GTR.
10 Yasargil et al. 40 had a perioperative mortality rate of 9% with a GTR of 90%, and Falbusch et al. 9 reported rates of 10.5% for recurrent craniopharyngiomas and 2.1% for primary craniopharyngiomas. These rates have dramatically decreased in most recent publications, 2,3,17 probably because of the increased awareness of surgeons and the general acceptance of adjuvant treatments for disease control. In agreement with recent literature, our perioperative mortality rate was 0%.
Tumor Recurrence and Adjuvant Therapies
Craniopharyngiomas have a tendency to recur even after apparent total removal, making adjuvant treatment essential. According to major literature studies, 9,37 the rate of recurrence ranges from 0% to 53% in cases of total removal and from 30% to 100% in cases of subtotal or partial removal. Our recurrence rate following GTR was 25%, and the overall recurrence rate for the entire cohort was 34.4%, which agrees with rates in the literature. However, it is impressive that pediatric patients, despite their higher resection rate, had a higher recurrence rate (41.2% vs 31.9% in adults), indicating the increased difficulty in treating this disease in children. Although the goal of surgery was the removal of > 95% of the tumor when GTR was considered dangerous, this strategy led to a recurrence rate of 40% (16 of 40 cases) compared with only 25% (6 of 24 cases) among patients who underwent GTR. This is the tradeoff for incomplete resection.
External beam irradiation is commonly used after partial resection and significantly improves the local tumor control rate. 18, 20, 39 Tumors that are purely cystic can be treated stereotactically with cyst decompression and intracavitary therapy. 16, 18, 20 Our experience with intracystic radiation ( 32 P) in 3 patients was successful in 2, for total resolution of a recurrent cystic lesion in 1 patient and a decrease of the lesion in the other patient. Stereotactic radiosurgery is effective in patients with small-volume lesions and is particularly useful for a well-defined residual mass after surgery or for small solid recurrent tumors. We used stereotactic radiosurgery in 6 patients with small residual tumor after EES and in 8 patients with recurrent craniopharyngioma with good results. Sys-temic chemotherapy and interferon-a may be beneficial for craniopharyngiomas that have undergone malignant transformation. 20 Our experience with 1 pediatric patient who received interferon for recurrent (benign) tumor was excellent, with total resolution of the mass. In any case, the management of craniopharyngioma must be individualized; treatment options must be tailored to the specific endocrine and neurological status, patient age, imaging features, and tumor consistency.
Disease Prognosis
Craniopharyngiomas are associated with decreased survival, with mortality rates 3-to 6-fold higher than those for the general population. 33 Recent studies have shown survival rates ranging from 83% to 93% at 10 years of follow-up. 20, 33 Besides the fatal surgical complications and deaths directly attributed to the tumor, low survival rates in the postoperative period are associated with cardiovascular, cerebrovascular, and respiratory problems in patients treated for craniopharyngioma. 10 An explanation for this morbidity is the possible early postoperative pituitary insufficiency or hypothalamic dysfunction, which is more likely after aggressive resection and, in some cases, radiation therapy. Patients with recurrent craniopharyngioma have a significantly lower probability of survival than those with primary tumors (at 10 years: 70% vs 99%). 20 Unfortunately, the recent application of EES for craniopharyngioma does not allow for long-term followup. Given this limitation in the current study, we cannot yet provide survival rates or long-term results for the patients with craniopharyngioma treated with EES.
Conclusions
The use of EES has been expanded to the treatment of large suprasellar craniopharyngiomas even with intraventricular extension. The goal of surgery should remain GTR or tumor removal > 95% when GTR is contraindicated. Regardless of the selected surgical approach, the high rate of recurrence often requires the use of adjuvant therapies. The surgical results of EES are acceptable and comparable to those for traditional approaches. Based on these results, EES can be considered an alternative to transcranial surgery for the management of craniopharyngioma.
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